Ibogaine for Other Addictions: Cocaine, Nicotine and Beyond

The opioid page covers the one indication with a real body of work behind it. This page covers everything else, and the shape of the answer is the finding.

Start with the registry, because it is one query

Searching the trial registry for ibogaine returns nine studies. Their indications are opioid use disorder and withdrawal, PTSD and traumatic brain injury, alcoholism, and general substance-use surveys.

Zero for cocaine. Zero for methamphetamine. Zero for nicotine or tobacco. Zero for cannabis. Zero for eating, gambling or any behavioural addiction.

That is not an argument that ibogaine does nothing for them. It is a statement about what has been asked, and nobody has asked. What the trials found sets out the registry in full.

Cocaine and crack, where the human data actually are

Two cohorts contain cocaine users, and neither can tell you about cocaine.

A series of 191 people detoxifying under inpatient monitoring covered opioid and cocaine users together, and reported reduced craving on questionnaires administered during the stay.

Seventy-five people in Brazil were studied retrospectively: alcohol, cannabis, cocaine and crack users, treated with ibogaine alongside psychotherapy. Sixty-one per cent were abstinent at the time of the survey. Those treated once reported a median of 5.5 months of abstinence, those treated more than once a median of 8.4 months, a difference the authors report at p < 0.001.

The honest position is that no cocaine-specific human finding exists, and the cohorts that include cocaine users were not built to produce one.

Methamphetamine, where it is rats only

There is real work here and it is entirely preclinical. Regional injection studies mapped where the analogue acts to reduce methamphetamine self-administration, to the medial habenula and the interpeduncular nucleus.

That is genuine pharmacology and it belongs on the brain regions page. It is not a human finding, and no human study of any size exists.

Nicotine, where the animal result argues with itself

Smoking is the question people ask most after opioids, and the answer is the most interesting negative on this page.

Injected into the medial habenula, the amygdala or the dorsolateral tegmentum, 18-MC reduced nicotine self-administration in rats. Injected into the interpeduncular nucleus, it increased it.

The interpeduncular nucleus is one of the two regions where the anti-addictive story is usually located. For nicotine it ran the other way, and the authors say so plainly.

There is no human evidence at all.

Cocaine again, and a result nobody quotes

One more preclinical finding deserves to be here rather than buried, because it points the wrong way.

In a conditioned place preference paradigm, 18-MC blocked acquisition of a cocaine preference, had no effect on its expression, and enhanced its reinstatement after extinction.

Reinstatement is the laboratory model of relapse. In that model, the compound made things worse.

Sugar and eating, where a study exists and says less than it seems

There is one obvious paper, and reading it carefully is the whole exercise.

18-MC reduced rats’ operant responding for sucrose and reduced free intake of sucrose, saccharin and saline. Chronic treatment affected weight gain in animals drinking sucrose solution.

At the highest dose it also reduced plain water intake, when no palatable fluid was available. A compound that reduces consumption of sweet things, salty things and water is not demonstrating a specific effect on sugar. It is reducing drinking.

That caveat is in the paper. It does not survive the journey into a headline about ibogaine and food addiction.

Cannabis

Cannabis users appear inside the Brazilian poly-drug cohort and nowhere else as a studied group. There is no cannabis-specific human or animal finding to report, and no registered study.

Gambling, gaming, pornography, body dysmorphia

Here the answer is shorter and firmer than anywhere else on this site.

There is no ibogaine research on any of them. No trial, no cohort, no case series, no animal model standing in for the behaviour. Not thin evidence or disputed evidence. None.

Where a claim about ibogaine and behavioural addiction appears, it is an extrapolation from the opioid literature, and the extrapolation has never been tested. Body dysmorphia is further still: it is not an addiction, and nothing in this literature addresses it.

What the pattern is telling you

The evidence is strongest for opioids, thinner for cocaine, preclinical for stimulants and nicotine, and absent thereafter. That gradient tracks what has been studied, and studying followed where people were already going for treatment.

So the shape of the evidence is a map of demand, not a map of pharmacology. It would look much the same whether ibogaine worked broadly or worked only for opioids, which is precisely why the gaps cannot be read either way.

Anyone weighing this should read it beside what ibogaine does to a heart. The cardiac risk does not shrink because the indication is less well studied. It is the same risk, taken for a weaker reason.